Get the Stockscreener App
0.78
5.50%
-0.0454
Bionomics Ltd. ADR stock is currently priced at $0.78, with a 24-hour trading volume of 175.38K.
It has seen a -5.50% decreased in the last 24 hours and a -16.14% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.7985 pivot point. If it approaches the $0.747 support level, significant changes may occur.
Previous Close:
$0.8254
Open:
$0.809
24h Volume:
175.38K
Market Cap:
$8.34M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-0.2396
EPS:
-3.2558
Net Cash Flow:
-
1W Performance:
+9.86%
1M Performance:
-16.14%
6M Performance:
-34.45%
1Y Performance:
-68.16%
1D Range:
$0.76
$0.8299
52W Range:
$0.65
$6.41
Bionomics Ltd. ADR Stock (BNOX) Company Profile
Name
Bionomics Ltd. ADR
Sector
Industry
Phone
61 8 8150 7400
Address
200 Greenhill Road, Eastwood
Bionomics Ltd. ADR Stock (BNOX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-22 | Initiated | Berenberg | Buy |
| Jan-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-22 | Initiated | Evercore ISI | Outperform |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
Bionomics Ltd. ADR Stock (BNOX) Latest News
Bionomics Ltd. ADR's latest rating changes from various analysts – Knox Daily - Knox Daily
Knox Daily
Closing Bell Recap: Bionomics Ltd. ADR (BNOX) Ends at 0.84, Reflecting a -14.97 Downturn – DWinneX - The Dwinnex
The Dwinnex
BNOX’s Stochastic Averages Dip: Analyzing Bionomics Ltd. ADR’s Stock Performance - The InvestChronicle
The InvestChronicle
Bionomics secures $70 million in private placement By Investing.com - Investing.com
Investing.com
BNOX's price-to-free cash flow ratio: What it means for investors – US Post News - US Post News
US Post News
Ratios Reveal: Breaking Down Bionomics Ltd. ADR (BNOX)'s Financial Health – DWinneX - The Dwinnex
The Dwinnex
Bionomics Ltd. ADR Stock (BNOX) Financials Data
There is no financial data for Bionomics Ltd. ADR (BNOX). Check out other stocks for more information.
About Bionomics Ltd. ADR
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
0.87%
0.21%
Cap:
|
Volume (24h):